Evommune

📍 Palo Alto, United States🗓 Founded 2020👥 53 employees💰 Last funded Nov 2024
Biotechnology Research🌐 evommune.com
Website LinkedIn
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease. Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2020
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United Kingdom
1
United States
1
Frequently asked questions
Who invested in Evommune?
Evommune has 2 investors on record on gritt.io, 2 mid-stage.
When did Evommune last raise funding?
The most recent investment in Evommune recorded on gritt.io was in November 2024.
When was Evommune founded?
Evommune was founded in 2020.
What industry is Evommune in?
Evommune operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Evommune based?
Evommune is headquartered in Palo Alto, United States.